Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors

Oncotarget

Volumn 6, Issue 11, 2015, Pages 8539-8551

  Gupta, Jalaj ^a   Igea, Ana ^a   Papaioannou, Marilena ^b   Lopez Casas, Pedro Pablo ^c   Llonch, Elisabet ^a   Hidalgo, Manuel ^c   Gorgoulis, Vassilis G ^b,d,e   Nebreda, Angel R ^a,f  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Colon cancer; Mouse xenograft; p38 MAPK; Therapy

Indexed keywords

INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PH 797804; STAT3 PROTEIN; 3 [3 BROMO 4 (2,4 DIFLUOROBENZYLOXY) 6 METHYL 2 OXO 1(2H) PYRIDINYL] N,4 DIMETHYLBENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CYTOKINE; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CACO 2 CELL LINE; CANCER INHIBITION; CELL SURVIVAL; COLON TUMOR; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; HT 29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, NEUROENDOCRINE; CELL DIFFERENTIATION; COLONIC NEOPLASMS; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETICS; LIVER TUMOR; METABOLISM; MUTATION; NUDE MOUSE; ONCOGENE RAS; PATHOLOGY; PHYSIOLOGY; SECONDARY; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CARCINOMA, NEUROENDOCRINE; CELL DIFFERENTIATION; COLONIC NEOPLASMS; CYTOKINES; GENES, RAS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MUTATION; NEOPLASM PROTEINS; NEOPLASM STAGING; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIDONES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928753284     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3816     Document Type: Article

References (46)

1. Fearon ER and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61:759-767.
2. Ullman TA and Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011; 140:1807-1816.
3. Siegel R, Desantis C and Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64:104-117.
4. Zacharakis M, Xynos ID, Lazaris A, Smaro T, Kosmas C, Dokou A, Felekouras E, Antoniou E, Polyzos A, Sarantonis J, Syrios J, Zografos G, Papalambros A and Tsavaris N. Predictors of survival in stage IV metastatic colorectal cancer. Anticancer Res. 2010; 30:653-660.
5. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J and Markowitz SD. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA. 2008; 105:4283-4288.
6. Kwak EL and Chung DC. Hereditary colorectal cancer syndromes: an overview. Clin Colorectal Cancer. 2007; 6:340-344.
7. Vagefi PA and Longo WE. Colorectal cancer in patients with inflammatory bowel disease. Clin Colorectal Cancer. 2005; 4:313-319.
8. Neufert C, Becker C and Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc. 2007; 2:1998-2004.
9. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans:better than commonly perceived-but they can be improved. Cancer Biol Ther. 2003; 2:S134-139.
10. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M and Merk J. Establishment of patientderived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008; 14:6456-6468.
11. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T and Bibby M. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer. 2004; 40:298-307.
12. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007; 13:3989-3998.
13. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006; 12:4652-4661.
14. Garralda E, Paz K, Lopez-Casas PP, Jones S, Katz A, Kann LM, Lopez-Rios F, Sarno F, Al-Shahrour F, Vasquez D, Bruckheimer E, Angiuoli SV, Calles A, Diaz LA, Velculescu VE, Valencia A, et al. Integrated Next Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. Clin Cancer Res. 2014. 20:2476-2484.
15. Wagner EF and Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009; 9:537-549.
16. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A and Nebreda AR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell. 2007; 11:191-205.
17. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H and Wagner EF. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet. 2007; 39:741-749.
18. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, Pasparakis M and Nebreda AR. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet. 2007; 39:750-758.
19. Caballero-Franco C, Choo MK, Sano Y, Ritprajak P, Sakurai H, Otsu K, Mizoguchi A and Park JM. Tuning of protein kinase circuitry by p38alpha is vital for epithelial tissue homeostasis. J Bio Chem. 2013; 288:23788-23797.
20. Gupta J, Del Barco Barrantes I, Igea A, Sakellariou S, Pateras IS, Gorgoulis VG and Nebreda AR. Dual Function of p38alpha MAPK in Colon Cancer: Suppression of Colitis-Associated Tumor Initiation but Requirement for Cancer Cell Survival. Cancer Cell. 2014; 25:484-500.
21. Otsuka M, Kang YJ, Ren J, Jiang H, Wang Y, Omata M and Han J. Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology. 2010; 138:1255-1265, 1265 e1251-1259.
22. Wakeman D, Schneider JE, Liu J, Wandu WS, Erwin CR, Guo J, Stappenbeck TS and Warner BW. Deletion of p38- alpha mitogen-activated protein kinase within the intestinal epithelium promotes colon tumorigenesis. Surgery. 2012; 152:286-293.
23. Chiacchiera F, Grossi V, Cappellari M, Peserico A, Simonatto M, Germani A, Russo S, Moyer MP, Resta N, Murzilli S and Simone C. Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Lett. 2012; 324:98-108.
24. Chiacchiera F and Simone C. Inhibition of p38alpha unveils an AMPK-FoxO3A axis linking autophagy to cancerspecific metabolism. Autophagy. 2009; 5:1030-1033.
25. Comes F, Matrone A, Lastella P, Nico B, Susca FC, Bagnulo R, Ingravallo G, Modica S, Lo Sasso G, Moschetta A, Guanti G and Simone C. A novel cell type-specific role of p38alpha in the control of autophagy and cell death in colorectal cancer cells. Cell Death Differ. 2007; 14:693-702.
26. Germani A, Matrone A, Grossi V, Peserico A, Sanese P, Liuzzi M, Palermo R, Murzilli S, Campese AF, Ingravallo G, Canettieri G, Tezil T and Simone C. Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38alpha modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. Cancer Lett. 2014; 344:110-118.
27. Goldstein DM, Kuglstatter A, Lou Y and Soth MJ. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem. 2010; 53:2345-2353.
28. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, Beug H, Ohlschlager P, Schutz A, Halbhuber KJ and Friedrich K. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 2005; 7:545-555.
29. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L and Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009; 15:103-113.
30. Knupfer H and Preiss R. Serum interleukin-6 levels in colorectal cancer patients--a summary of published results. Int J Colorectal Dis. 2010; 25:135-140.
31. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T and Sekine I. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol. 2005; 58:833-838.
32. Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, Nguyen PM, Preaudet A, Farid R, Edwards KM, Boglev Y, Luwor RB, Jarnicki A, Horst D, Boussioutas A, Heath JK, et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 2013; 24:257-271.
33. Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, Huels D, Olson MF, Das S, Nibbs RJ and Sansom OJ. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest. 2012; 122:3127-3144.
34. Ventura JJ, Hubner A, Zhang C, Flavell RA, Shokat KM and Davis RJ. Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell. 2006; 21:701-710.
35. Kopetz S, Lemos R and Powis G. The promise of patientderived xenografts: the best laid plans of mice and men. Clin Cancer Res. 2012; 18:5160-5162.
36. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G and Karin M. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogeninduced compensatory proliferation and liver tumorigenesis. Cancer Cell. 2008; 14:156-165.
37. Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, Petruzzelli M, Salvatore L, Moschetta A and Simone C. p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ. 2009; 16:1203-1214.
38. Pereira L, Igea A, Canovas B, Dolado I and Nebreda AR. Inhibition of p38 MAPK sensitizes tumour cells to cisplatininduced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med. 2013; 5:1759-1774.
39. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ and Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359:1757-1765.
40. Katoh H, Wang D, Daikoku T, Sun H, Dey SK and Dubois RN. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell. 2013; 24:631-644.
41. Tiedje C, Holtmann H and Gaestel M. The role of mammalian MAPK signaling in regulation of cytokine mRNA stability and translation. J Interferon Cytokine Res. 2014; 34:220-232.
42. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, Matthews V, Schmid RM, Kirchner T, Arkan MC, Ernst M and Greten FR. gp130- mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 2009; 15:91-102.
43. Menon MB, Kotlyarov A and Gaestel M. SB202190- induced cell type-specific vacuole formation and defective autophagy do not depend on p38 MAP kinase inhibition. PloS One. 2011; 6:e23054.
44. Paillas S, Boissiere F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vie N, Marzi L, Cortijo C, Ait-Arsa I, Askari N, Pourquier P, Martineau P, Del Rio M and Gongora C. Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Res. 2011; 71:1041-1049.
45. Fan XJ, Wan XB, Fu XH, Wu PH, Chen DK, Wang PN, Jiang L, Wang DH, Chen ZT, Huang Y, Wang JP and Wang L. Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer. Tumour Biol. 2014; 35:10487-10495.
46. Yang SY, Miah A, Sales KM, Fuller B, Seifalian AM and Winslet M. Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment. Int J Oncol. 2011; 38:1695-1702.